The effector/exhausted ratio in the early stages of lung cancer is intermediate between that of normal lung tissue and advanced stages, revealing the dynamic evolution of CD8+ T cell subsets during lung cancer progression (19). This evidence concerns the gene CD8A and lung carcinoma.